SphK2 is also a well-established anticancer target, with the SphK2 inhibitor opaganib (ABC294640, Ki = 9.8 μM) successfully reaching phase 2 clinical trials for prostate cancer (Figure 1) [20,21,22,23,24]. This evidence concerns the gene SPHK2 and prostate carcinoma.